Genomic alterations in circulating tumor DNA (ctDNA) are associated with clinical outcomes in treatment-naive metastatic castration-resistant prostate cancer (mCRPC) patients commencing androgen receptor (AR)-targeted therapy

Authors:
  • AWA.W. Wyatt
    A.W. Wyatt
  • MAM. Annala
    M. Annala
  • KBK. Beja
    K. Beja
  • SPS. Parimi
    S. Parimi
  • GVG. Vandekerkhove
    G. Vandekerkhove
  • EWE. Warner
    E. Warner
  • MZM. Zulfiqar
    M. Zulfiqar
  • DFD. Finch
    D. Finch
  • COC. Oja
    C. Oja
  • JVJ. Vergidis
    J. Vergidis
  • MNM. Nykter
    M. Nykter
  • MGM.E. Gleave
    M.E. Gleave
Publisher website
Google Scholar
Abstract
Background: There are no established genomic biomarkers to predict response to the AR-targeted therapies enzalutamide and abiraterone, partly due to the impracticality of sampling tissue in a bone-predominant metastatic disease. Cell-free DNA (cfDNA) is a promising “liquid biopsy” approach to genomic characterization of mCRPC.